

1 GORDON SILVER  
MOLLY M. REZAC, ESQ.  
2 Nevada Bar No. 7435  
Email: mrezac@gordonsilver.com  
3 JUSTIN J. BUSTOS, ESQ.  
Nevada Bar No. 10320  
4 Email: jbustos@gordonsilver.com  
100 W. Liberty Street  
5 Suite 940  
Reno, NV 89501  
6 Tel: (775) 343-7500  
Fax: (775) 786-0131  
7

**Of Counsel:**

8 JAMES B. MONROE, ESQ.  
9 JUSTIN J. HASFORD, ESQ.  
FINNEGAN HENDERSON FARABOW  
10 GARRETT & DUNNER, LLP  
901 New York Avenue, NW  
11 Washington, DC 20001-4413  
Tel: (202) 408-4000  
12 Fax: (202) 408-4400

13 *Attorneys for Plaintiff Ferring B.V.*

14  
15 **UNITED STATES DISTRICT COURT**  
16 **DISTRICT OF NEVADA**

17 FERRING B.V., 18 Plaintiff, 19 v. 20 APOTEX INC. 21 and 22 APOTEX CORP., 23 Defendants. 24	Case No: 2:12-cv-1941  <b><u>COMPLAINT FOR PATENT INFRINGEMENT</u></b>
--	--

25 ...  
26 ...  
27 ...  
28

1 Plaintiff Ferring B.V. (“Ferring”), by way of Complaint against Defendants Apotex Inc.  
2 and Apotex Corp. (collectively “Apotex”), alleges as follows:

3 **THE PARTIES**

4 1. Ferring is a corporation organized and existing under the laws of the Netherlands  
5 with its corporate headquarters at Polaris Avenue 144, 2132 JX Hoofddorp, The Netherlands.  
6 Ferring is engaged in the research, development, manufacture and sale of pharmaceutical  
7 products.  
8

9 2. Upon information and belief, Apotex Inc. is a corporation organized and existing  
10 under the laws of Canada, having a principal place of business at 150 Signet Drive, Weston,  
11 Toronto, Ontario, Canada M9L 1T9.

12 3. Upon information and belief, Apotex Corp. is a corporation organized and  
13 existing under the laws of the State of Delaware, and its principal place of business is located at  
14 2400 North Commerce Parkway, Suite 400, Weston, Florida 33326. Upon information and  
15 belief, Apotex Corp. is a wholly-owned subsidiary of Apotex Inc.  
16

17 **NATURE OF THE ACTION**

18 4. This is an action for infringement of United States Patent Number 8,273,795 (“the  
19 ’795 patent”), arising under the United States patent laws, Title 35, United States Code, § 100 *et*  
20 *seq.*, including 35 U.S.C. §§ 271 and 281. This action relates to Apotex Inc.’s filing of an  
21 Abbreviated New Drug Application (“ANDA”) under Section 505(j) of the Federal Food, Drug  
22 and Cosmetic Act (“the Act”), 21 U.S.C. § 355(j), seeking U.S. Food and Drug Administration  
23 (“FDA”) approval to market generic tablets containing 650 mg tranexamic acid (“Apotex’s  
24 generic tranexamic acid tablets”).  
25

26 **JURISDICTION AND VENUE**

27 5. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a).  
28

1           6.       Upon information and belief, this Court has jurisdiction over Apotex Inc. Upon  
2 information and belief, Apotex Inc. is in the business of manufacturing, marketing, importing  
3 and selling pharmaceutical drug products, including generic drug products. Upon information  
4 and belief, Apotex Inc. directly, or through its wholly-owned subsidiaries, including Apotex  
5 Corp., manufactures, markets and sells generic drug products throughout the United States and in  
6 this judicial district, and this judicial district is a likely destination of Apotex's generic  
7 tranexamic acid tablets.  
8

9           7.       Upon information and belief, this Court has jurisdiction over Apotex Corp. Upon  
10 information and belief, Apotex Corp. directly, or indirectly, manufactures, markets and sells  
11 generic drug products, including generic drug products manufactured by Apotex Inc., throughout  
12 the United States and in this judicial district. Upon information and belief, Apotex Corp.  
13 purposefully has conducted and continues to conduct business in this judicial district.  
14

15           8.       Upon information and belief, venue is proper in this judicial district under 28  
16 U.S.C. §§ 1391(c) and (d), and § 1400(b).  
17

**COUNT FOR PATENT INFRINGEMENT**

18           9.       The U.S. Patent and Trademark Office ("PTO") issued the '795 patent on  
19 September 25, 2012, and the '795 patent expires on March 4, 2025. The '795 patent claims,  
20 *inter alia*, methods of treating menorrhagia with tranexamic acid formulations. Ferring is the  
21 owner of the '795 patent. A copy of the '795 patent is attached hereto as **Exhibit A**.  
22

23           10.       Ferring Pharmaceuticals AS is the holder of New Drug Application ("NDA") No.  
24 02-2430 for tranexamic acid tablets, which the FDA approved on November 13, 2009. The '795  
25 patent is listed for NDA No. 02-2430 in the FDA's Approved Drug Products with Therapeutic  
26 Equivalence Evaluations ("the Orange Book").  
27  
28

1           11.     Ferring sells 650 mg dosage strengths of tranexamic acid tablets in the United  
2 States under the trademark Lysteda<sup>®</sup>.

3           12.     Upon information and belief, Apotex Inc. filed with the FDA ANDA No. 202286,  
4 under Section 505(j) of the Act, 21 U.S.C. § 355(j).

5           13.     Upon information and belief, Apotex Inc.'s ANDA No. 202286 seeks FDA  
6 approval to sell in the United States generic tranexamic acid tablets containing 650 mg of  
7 tranexamic acid intended to be generic versions of Lysteda<sup>®</sup>.

8           14.     On November 8, 2012, Ferring received a letter from Apotex Inc., dated  
9 November 5, 2012, purporting to be a Notice of Certification for ANDA No. 202286 ("Apotex's  
10 notice letter") under Section 505(j)(2)(B)(ii) of the Act, 21 U.S.C. § 355(j)(2)(B)(ii), and 21  
11 C.F.R. § 314.95(c).

12           15.     Apotex's notice letter alleges that Apotex Inc. has submitted to the FDA ANDA  
13 No. 202286 seeking FDA approval to sell in the United States generic tranexamic acid tablets  
14 containing 650 mg of tranexamic acid intended to be generic versions of Lysteda<sup>®</sup>.

15           16.     Under 35 U.S.C. § 271(e)(2)(A), Apotex Inc. has infringed at least one claim of  
16 the '795 patent by submitting, or causing to be submitted to the FDA, ANDA No. 202286  
17 seeking approval for the commercial marketing of Apotex's generic tranexamic acid tablets  
18 before the expiration date of the '795 patent.

19           17.     Upon information and belief, ANDA No. 202286 seeks approval of Apotex's  
20 generic tranexamic acid tablets that are the same, or substantially the same, as Lysteda<sup>®</sup>.

21           18.     Upon information and belief, Apotex's generic tranexamic acid tablets will, if  
22 approved and marketed, infringe at least one claim of the '795 patent.  
23  
24  
25  
26  
27  
28

1           19.    Upon information and belief, Apotex Inc. will, through the manufacture, use,  
2 import, offer for sale and/or sale of Apotex's generic tranexamic acid tablets, contributorily  
3 infringe and/or induce infringement of at least one claim of the '795 patent.

4           20.    Upon information and belief, Apotex Inc.'s actions relating to ANDA No. 202286  
5 complained of herein were done with the cooperation, the participation, the assistance of, and at  
6 least in part for the benefit of, Apotex Corp.

7  
8           **WHEREFORE**, Plaintiff Ferring respectfully requests that the Court enter judgment in  
9 its favor and against Defendants Apotex Inc. and Apotex Corp. on the patent infringement claims  
10 set forth above and respectfully requests that this Court:

- 11           1)    enter judgment that, under 35 U.S.C. § 271(e)(2)(A), Apotex has infringed at least  
12 one claim of the '795 patent through Apotex Inc.'s submission of ANDA No.  
13 202286 to the FDA to obtain approval for the commercial manufacture, use,  
14 import, offer for sale and/or sale in the United States of Apotex's generic  
15 tranexamic acid tablets before the expiration of the '795 patent;
- 16           2)    order that the effective date of any approval by the FDA of Apotex's generic  
17 tranexamic acid tablets be a date that is not earlier than the expiration of the '795  
18 patent, or such later date as the Court may determine;
- 19           3)    enjoin Apotex from the commercial manufacture, use, import, offer for sale  
20 and/or sale of Apotex's generic tranexamic acid tablets until the expiration of the  
21 '795 patent, or such later date as the Court may determine;
- 22           4)    enjoin Apotex and all persons acting in concert with Apotex from seeking,  
23 obtaining or maintaining approval of Apotex Inc.'s ANDA No. 202286 until the  
24 expiration of the '795 patent;
- 25  
26  
27  
28

- 1 5) declare this to be an exceptional case under 35 U.S.C. §§ 285 and 271(e)(4) and  
2 award Ferring costs, expenses and disbursements in this action, including  
3 reasonable attorneys fees; and  
4  
5 6) award Ferring such further and additional relief as this Court deems just and  
6 proper.

7 DATED this 9<sup>th</sup> day of November, 2012.

8 GORDON SILVER

9 By: \_\_\_\_\_/s/ Molly Malone Rezac

10 GORDON SILVER  
11 MOLLY M. REZAC, ESQ.  
12 Nevada Bar No. 7435  
13 Email: mrezac@gordonsilver.com  
14 JUSTIN J. BUSTOS, ESQ.  
15 Nevada Bar No. 10320  
16 Email: jbustos@gordonsilver.com  
17 100 W. Liberty Street  
18 Suite 690  
19 Reno, NV 89501  
20 Tel: (775) 343-7500  
21 Fax: (775) 786-0131

22 **Of Counsel:**

23 JAMES B. MONROE, ESQ.  
24 JUSTIN J. HASFORD, ESQ.  
25 FINNEGAN HENDERSON FARABOW  
26 GARRETT & DUNNER, LLP  
27 901 New York Avenue, NW  
28 Washington, DC 20001-4413  
Tel: (202) 408-4000  
Fax: (202) 408-4400

*Attorneys for Plaintiff Ferring B.V.*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**TABLE OF EXHIBITS**

<b>Exhibit</b>	<b>Exhibit Description</b>	<b>Pages<sup>1</sup></b>
A	Copy of the '795 patent	

---

<sup>1</sup> Exhibit page count is exclusive of exhibit slip sheets.